Skip to content
OpenCapital
Get started

PTC Therapeutics PTCT Contingent consideration fair value adjustments

Contingent consideration fair value adjustments at other companies

Biogen logo
BiogenBIIB
——
Insmed logo
InsmedINSM
——

Other financials

Income statement

See full
Revenue$272.6M-76.8%
Operating income$45.0M-95.4%
Net income-$2.8M-100%
EPS (diluted)-$0.03-100%

Balance sheet

See full
Cash & equivalents$834.0M-43.7%
Total debt$395.1M+0.1%
Total equity-$180.5M+2.9%
Total assets$2.9B+8.0%

Cash flow

See full
Operating cash flow-$59.0M-107%
CapEx$1.2M-30.6%
Free cash flow-$60.2M-107%

Valuation

See full
Market cap$6.55B+40.3%
Enterprise value$6.11B+77.3%
P/E8×—
P/S7.9×+5.3×

Profitability

See full
Gross margin96%—
Operating margin1.6%-38.7pp
Net margin42.3%+27.4pp
FCF margin39.1%+32.8pp

Returns & leverage

See full
Return on equity-216.7%—
Debt / equity372.3×—
Current ratio2.4×-1.5×

Where this comes from

Reported directly by PTC Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.

The official record: PTC Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTC Therapeutics's contingent consideration fair value adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is PTC Therapeutics's contingent consideration fair value adjustments?
PTC Therapeutics (PTCT) reported contingent consideration fair value adjustments of -$800K in Q1 2025.
How has PTC Therapeutics's contingent consideration fair value adjustments changed year-over-year?
PTC Therapeutics's contingent consideration fair value adjustments decreased by 700.0% year-over-year, from -$100K to -$800K.
What is the long-term trend for PTC Therapeutics's contingent consideration fair value adjustments?
Over 2 years (2021 to 2024), PTC Therapeutics's contingent consideration fair value adjustments has grown at a 199.2% compound annual growth rate (CAGR), from -$500K to -$4.48M.